Search bioRxiv⌕ Search

bioRxiv · 10.64898/2025.12.24.696284

CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteins

Abstract

Acute myeloid leukemia (AML), the most common hematologic malignancy, generally has a poor prognosis. Despite initial favorable responses to the BCL2 inhibitor venetoclax (VEN), remission is transient, and AML is eventually fatal. Resistance to VEN is primarily due to the overexpression of anti-apoptotic proteins, including MCL-1, BCL2L1 (BCL-XL), and BCL2A1. Casein kinase II (CK2) is a serine-threonine kinase and a known suppressor of apoptosis. We and others have reported that protein kinase CK2 activity is high in leukemic stem cells (LSCs) and associated with resistance to chemotherapy. We have shown that the selective CK2 inhibitor, CX-4945, suppresses BCL-XL and has a significant anti-tumor effect in AML preclinical models. CK2 expression and activity are high in venetoclax-resistant AML (VR-AML) cell lines. Genetic and pharmacological inhibition of CK2 significantly altered VR-AML gene signature, decreased MCL-1 protein level, increased BH3 priming and sensitized VR-AML cells to apoptosis. More importantly, CX-4945 selectively targeted LSCs (CD34+CD38-) and chemoresistant (CD123+CD47+) subpopulation in VR-AML. CX-4945 combined with VEN decreased leukemia burden and prolonged the survival of VR-AML cell line-derived and patient-derived xenografts compared to either drug alone. The combinatorial treatment was well tolerated in mice without additional myelosuppression or organ toxicity. CX-4945 (silmitasertib) is being tested in several early-phase clinical trials against adult and pediatric cancers. These preclinical results support the use of CX-4945 in combination with VEN to overcome resistance to apoptosis and re-sensitize VR-AML to chemotherapy. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=135 SRC="FIGDIR/small/696284v1_ufig1.gif" ALT="Figure 1"> View larger version (43K): org.highwire.dtl.DTLVardef@6a902forg.highwire.dtl.DTLVardef@2028f5org.highwire.dtl.DTLVardef@160fd4dorg.highwire.dtl.DTLVardef@95da53_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Daniyal, M., Rajaiah, R., Golla, U., Pandiyan Shanmugam, M., Duke, K., Mercer, K., Uzun, Y., Valensi, H., Hengst, J., Dovat, S., Qiu, Y., Huang, S., Behura, C. G.. 2025-12-26. CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteins. https://doi.org/10.64898/2025.12.24.696284

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Distinct changes in brain and peripheral oxygen levels induced by synthetic opioids of the nitazene family

Nitazenes are a category of synthetic opioids, some of which have high analgesic potential but also high toxicity, which has historically prevented their development as therapeutic drugs. Like fentanyl, nitazenes induce respiratory depression, a primary factor in their toxicity. Recently, a nitazene derivative called N-desethyl-fluornitrazene (DFNZ) was shown to have high analgesic properties with weak hypoxic effects. To better characterize the hypoxic effects of DFNZ relative to its parent, fluornitrazene (FNZ) and the prototypical nitazene etonitazene, we used amperometric oxygen sensors in freely moving rats to examine oxygen dynamics in the nucleus accumbens (NAc) and the subcutaneous space, using fentanyl as a comparison. All drugs induced similar patterns of subcutaneous hypoxia, with rapid dose-dependent oxygen decreases. In the NAc, all opioids, except DFNZ, at low iv doses (1-5 g/kg) induced moderate but significant brain oxygen increases. At higher doses (>10 g/kg), oxygen levels for all opioids, except DFNZ, showed a biphasic response; robust hypoxia followed by a weaker rebound-like hyperoxia. Etonitazene at 30 g/kg had the largest and most prolonged brain hypoxia compared to the other drugs, without the rebound-like hyperoxia. These findings indicate that etonitazene and FNZ mimic the effects of fentanyl, inducing dose-dependent brain and peripheral hypoxia. In contrast, DFNZ induces very weak hypoxia seen minimally at very high iv doses (300-1000 g/kg). Our findings substantiate the low hypoxic potency of DFNZ and indicate that not all nitazenes are characterized by high potential for toxicity. As such, the development of nitazenes as analgesics should not be categorically dismissed.

pharmacology and toxicology↗

The key role of oxidation state and flake size in the ecotoxicological impact of industrial graphene oxide nanoflakes

Graphene oxide (GO) is a widely used nanomaterial across various scientific and technological fields. Environmental exposure to GO and consequent ecotoxicological effects have been largely reported. Despite the significant efforts and illuminating conclusions, establishing fair pairwise correlations between material and toxicity descriptors remains challenging and controversial. Key drawbacks in GO ecotoxicological studies to date include a lack of standardized materials, poorly defined descriptors, and insufficient material variants. Here, we establish the first comprehensive framework to tackle the multidimensional ecotoxicology of GO. We perform thorough material characterization to derive descriptors that precisely define four key GO variants used in industrial scale-up, with differing flake granularity and oxidation extent. These GO variants are evaluated against toxicological endpoint descriptors across two animal models (Daphnia magna and Caenorhabditis elegans) and two plant models (rice and pepper). Our findings underscore the inherently multidimensional nature of GO toxicity by identifying key physicochemical properties associated with it. This study provides an unprecedented platform for parametrizing GO materials using material and toxicity descriptors to contribute to nanomaterial safety.

pharmacology and toxicology↗

The activation-deactivation cycle of human PIEZO1

PIEZO1 is a cation channel that is primarily activated through mechanical force, and activation has been shown to be influenced by membrane curvature. PIEZO1 is ubiquitously expressed and plays critical roles in various patho-/physiological processes such as inflammatory diseases or red blood cell volume regulation. Here we combine coarse-grained and atomistic simulations in which human PIEZO1 is embedded in a curved membrane and subjected to simulations under controlled membrane tension and a physiological transmembrane potential, allowing the gating cycle to be reconstructed at atomic resolution. Systematic pressure adaptation identifies an activation regime in which the channel flattens progressively, and ion permeation quantitatively reproduces the experimental conductance of 36 pS. Furthermore, the R2456-E2117 salt bridge couples pore lipid retention to the anchor domain and disrupting it reproduces the phenotypes of the disease-associated R2456H and R2456C variants. PIEZO activation is transmitted through an interconnected network of contact rearrangements that ultimately reshapes the yoda1 binding pocket at the THU8/THU9 interface. This state-dependent remodelling rationalises the pharmacology of yoda1 and offers a framework for the structure-based design of PIEZO1 modulators.

pharmacology and toxicology↗